Open-Label, Single Arm, Phase 3B, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT 199) in Relapsed/Refractory Subjects with Chronic Lymphocytic Leukemia (CLL) (VENICE I)
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2017
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms VENICE I
- Sponsors AbbVie
- 15 Aug 2017 Planned End Date changed from 1 Oct 2022 to 23 Oct 2022.
- 15 Aug 2017 Planned primary completion date changed from 1 Feb 2020 to 23 Oct 2022.
- 10 Jun 2017 Biomarkers information updated